<SEC-DOCUMENT>0001564590-20-027369.txt : 20200528
<SEC-HEADER>0001564590-20-027369.hdr.sgml : 20200528
<ACCEPTANCE-DATETIME>20200528171546
ACCESSION NUMBER:		0001564590-20-027369
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200528
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200528
DATE AS OF CHANGE:		20200528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		20922308

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abio-8k_20200528.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-8k_20200528.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:justify;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K </p>
<p style="text-align:center;margin-top:9pt;line-height:4pt;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported):<font style="color:#000000;font-size:12pt;"> </font><font style="color:#000000;">May 28, 2020</font></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter)</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">000-22873</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">36-3855489</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="top"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11080 CirclePoint Road, Suite 140, Westminster, CO</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">80020</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:34.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:32.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (720) 940-2200</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former Name or Former Address, if Changed Since Last Report) </p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:9pt;margin-bottom:0pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-top:9pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:12pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:86.67%;">
<tr>
<td style="width:25.83%;"></td>
<td style="width:20%;"></td>
<td style="width:40.83%;"></td>
</tr>
<tr style="height:12.65pt;">
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr style="height:16.6pt;">
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABIO</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:36pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Capital Market</p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="text-align:justify;margin-top:4pt;border-top:Solid 0.75pt #000000;padding-top:0pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section&#160;8 &#8212; Other Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.01.</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Other Events. </p></td>
</tr>
</table></div>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 28, 2020, ARCA biopharma, Inc. announced the planned AB201 development program for treatment of COVID-19 associated coagulopathy.&nbsp;&nbsp;The press release related to these items is filed as Exhibit&#160;99.1 hereto, the contents of which are incorporated herein by reference.</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the planned development described above, ARCA biopharma, Inc. is supplementing the risk factors previously disclosed in its most recent periodic reports filed under the Securities Exchange Act of 1934, as amended, with the following risk factors:</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we encounter difficulties enrolling patients in our planned clinical trial of AB201, any potential enrollment milestones or potential regulatory approvals could be delayed or otherwise adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may encounter difficulty enrolling a sufficient number of patients in the trial, due to circumstances which are outside our control, including improvements in the COVID-19 pandemic resulting from the development of vaccines and therapies that limit the availability of study participants.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients in our clinical trial of AB201, we may need to delay or terminate our trial, which would have a negative impact on our business. Delays in enrolling patients in the planned clinical trial of AB201 would also adversely affect our ability to meet projected enrollment milestones or timelines for completing the study and obtaining regulatory approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AB201 may not yield results that will enable us to further develop it as a therapy and obtain regulatory approvals necessary to it as a drug.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will receive regulatory approval for our product candidates only if we can demonstrate, in carefully designed and conducted clinical trials, that the product candidate is safe and effective. We do not know whether the planned or any future clinical trials for AB201 will demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals or will result in marketable products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results from preclinical testing and early clinical trials may not be predictive of results from our planned studies of AB201. We may suffer significant setbacks in advanced clinical trials, even after seeing promising results in earlier studies. Based on results at any stage of clinical trials, we may decide to repeat or redesign a trial or discontinue development of one or more of our product candidates, including AB201. If we fail to adequately demonstrate the safety and efficacy of our AB201 product candidate, we will not be able to obtain the required regulatory approvals to commercialize it and our business, results of operations and financial condition would be materially adversely affected.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administering AB201 to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of AB201 and could result in the FDA or other regulatory authorities denying approval of AB201 for any or all targeted indications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>We may not achieve our projected development goals in the time frames we announce and expect.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We set goals for, and make public statements regarding, the timing of certain accomplishments, such as the planned submission of an IND application for AB201 as a potential treatment for COVID-19 with the FDA, the steps for commencing and continuing our clinical trials, the disclosure of trial results, the obtainment of regulatory approval and the sale of drug product, which we sometimes refer to as milestones. These milestones may not be achieved, and the actual timing of these events can vary dramatically due to a number of factors such as FDA&#8217;s rejection of our IND application, delays or failures in our clinical trials, disagreements with any collaborative partners, the uncertainties inherent in the regulatory approval process and manufacturing scale-up, delays in achieving manufacturing or marketing arrangements sufficient to commercialize our products or an inability to finance in a timely manner. There can be no assurance that we will make regulatory submissions or receive regulatory approvals as planned. If we fail to achieve one or more of these milestones as planned, our business will be materially adversely affected.</p>
<p style="margin-top:13pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Section 9 &#8212; Financial Statements and Exhibits </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01. Financial Statements and Exhibits. </p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits. </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:10.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:78.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Number</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="abio-ex991_6.htm"><font style="text-decoration:underline;">Press Release titled &#8220;ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy&#8221; dated May 28, 2020</font></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:62.25%;"></td>
<td style="width:4.17%;"></td>
<td style="width:5.5%;"></td>
<td style="width:28.08%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 28, 2020</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma, Inc.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant)</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="bottom"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brian L. Selby</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President, Finance and Chief Accounting Officer</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abio-ex991_6.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
abio-ex991_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.38 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvebfb4t3mpa000001.jpg" title="" alt="" style="width:203px;height:69px;"></p>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:48.89%;"><br />&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ARCA Biopharma announces AB201 development program for treatment of covid-19 ASSOCIATED COAGulopAthy</p>
<p style="text-align:center;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">------------------------------------------------------------------------------------------------------------ </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><a name="_Hlk40971639"></a><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Previous safety data in more than 700 patients through Phase 2 may enable more rapid development</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">ARCA anticipates filing an IND in the third quarter of 2020 and initiating late-stage clinical testing in the second half of this year</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:4pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Prior rNAPc2 results treating Ebola and Marburg viral infections in non-human primate trials support development as treatment for RNA virus associated disease</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:12pt;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;">AB201 (rNAPc2) is a potent inhibitor of tissue factor, a key driver of the viral infection process and associated inflammatory response, including virus-associated coagulopathy</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk41497613"></a>Westminster, CO, May 28, 2020<font style="font-style:normal;"> &#8211; ARCA biopharma, Inc. (Nasdaq: ABIO) today announced a new development program to evaluate<a name="_Hlk41497613"></a> AB201 (rNAPc2), a potent, selective inhibitor of tissue factor (TF), as a potential treatment for COVID-19 associated coagulopathy (CAC) and the related inflammatory response. CAC is one of the most serious adverse effects seen in COVID-19 patients. AB201 has previously undergone clinical testing through Phase 2 in more than 700 patients for other indications, generating substantial safety data, which the Company believes may enable more rapid development. ARCA anticipates filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the third quarter and initiating late-stage clinical testing in the second half of this year.</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TF is the protein responsible for initiating the primary or extrinsic coagulation pathway. TF has been identified as playing a central role in the inflammatory response to viral infections and in the process of viral dissemination. AB201 (rNAPc2), a single-chain, 85 amino acid, recombinant protein, has previously undergone Phase 1 and Phase 2 testing in more than 700 patients, including as an anti-thrombotic agent in the setting of acute myocardial infarction (MI), where it showed efficacy in inhibiting the TF pathway and was well tolerated at therapeutic doses. Recent research suggests that the disease syndrome caused by coronavirus may have much in common with other coagulopathic disorders in which the blood's ability to coagulate (form clots) is impaired by consumption of clotting factors (disseminated intravascular coagulation, DIC). For example, filovirus infections such as Ebola and other hemorrhagic fevers are characterized by dysregulated activation of the TF pathway, resulting in abnormal systemic coagulation and related inflammation, leading to organ failure and mortality. Recent mechanistic discoveries, as well as data from studies in non-human primates (NHPs) given lethal doses of Ebola or Marburg filoviruses demonstrating mortality reductions, decreases in inflammatory biomarkers and reduction in viral load, indicate that AB201 may have important antiviral and anti-inflammatory activity in addition to its anticoagulant effects. Collectively, the Company believes these observations provide a strong rationale for investigating AB201 as a treatment for COVID-19, the disease caused by SARS CoV-2 virus.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><a name="_Hlk41044188"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">COVID-19 disease is associated with </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a significant</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> incidence of coagulation-related adverse events, including stroke, MI (i.e., heart attack), pulmonary emboli, and disseminated intravascular coagulation (DIC), a condition in which small blood clots develop throughout the bloodstream. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A commonly used</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> biomarker for </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assessing</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk41044188"></a> coagulation activation is a D-dimer test, which is elevated in approximately 50% of hospitalized COVID-19 patients and is directly associated with adverse clinical outcomes. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ebola or Marburg NHP models</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AB201</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inhibited the DIC process, as measured by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lowered D-dimer levels</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">which the Company believes </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provid</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> further support for its therapeutic potential </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CAC</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> t</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he efficacy of AB201 against COVID-19 disease </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">may not</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be affected by </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potential </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mutations of the SARS CoV-2 virus, would be additive with therapeutics inhibiting virus-cell binding or viral RNA polymerase, and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">could</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> be effective against other coagulopathy-associated viruses</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Wolfram Ruf, Scientific Director of the Center for Thrombosis and Hemostasis at the Johannes Gutenberg University Medical Center Mainz, Germany, and Professor at Scripps Research, La Jolla, CA, commented, &#8220;Our research, combined with the accumulating evidence on the clinical importance of large and small vessel thromboses in the COVID-19 infected patients, points to a potentially important role for the tissue factor pathway in viral infection, inflammatory response and the development of coagulopathy. With its properties in modulating the TF pathway and the evidence from its prior development, rNAPc2 has the potential to be a uniquely beneficial therapy for patients with COVID-19.&#8221;</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Michael Bristow, ARCA&#8217;s President and Chief Executive Officer, who is also an American Heart Association (AHA) funded COVID-19 investigator, commented, &#8220;During this global health crisis, we believe it is important to rapidly and collaboratively evaluate multiple technologies to address COVID-19 and the associated pathologic host responses. The combination of anticoagulation, anti-inflammatory effects and antiviral activity have the potential to make AB201 a unique therapeutic to treat patients afflicted with COVID&#8209;19 while vaccine development is underway and for patients for whom a vaccine is not effective. We believe this therapeutic approach may also have potential to address future outbreaks of diseases related to other RNA viruses.&#8221; </p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Next Steps:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Company anticipates filing an IND application for AB201 as a potential treatment for COVID-19 with the FDA in the third quarter of this year.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">In collaboration with the Colorado Prevention Center, the University of Colorado's Academic Research Organization directed by Marc Bonaca, MD, a vascular and anti-coagulation clinical trialist, a Phase&#160;2B/3 clinical trial protocol is being developed for hospitalized COVID-19 patients with elevated D-dimer levels.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Pending FDA concurrence and obtaining trial funding, ARCA estimates initiating late-stage clinical testing of AB201 in the second half of 2020.</p></td></tr></table></div>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Bonaca commented, &#8220;The thrombotic complications of COVID-19 are severe and stem directly from viral activity and vascular inflammation. By targeting tissue factor and the extrinsic pathway, AB201 may offer a unique approach that could simultaneously reduce the severity of the viral infection as well as reduce the risk of its thrombotic complications. The extensive Phase 2 safety experience in other diseases could enable more rapid development via a Phase 2B-Phase 3 adaptive program."</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AB201 is manufactured using a proven process that enables production at commercial scale, should clinical testing provide sufficient evidence of efficacy to seek regulatory approval.</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About the Novel Coronavirus SARS-CoV-2 (and COVID-19 Disease)</font></p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SARS-CoV-2 is a new coronavirus identified in late 2019 and belongs to a family of enveloped RNA viruses that include Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS-CoV), both of which caused serious human infections of respiratory system. The disease caused by the SARS-CoV-2 virus has been designated COVID-19. Since this outbreak was first reported in late-2019, the virus has infected over 5.4 million people and has caused over 349,000 reported deaths (as of May 27, 2020). It has been declared a pandemic by the World Health Organization. Currently there is no vaccine or curative drug therapy for COVID-19.</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About ARCA biopharma</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA is developing AB201 as a potential treatment for diseases caused by RNA viruses, initially focusing on COVID-19. ARCA is also developing Gencaro<sup style="font-size:85%;line-height:120%;vertical-align:top">TM</sup> (bucindolol hydrochloride), an investigational, pharmacologically unique beta-blocker and mild vasodilator, as a potential treatment for atrial fibrillation in heart failure patients. ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically targeted AF prevention treatment. The U.S. FDA has granted the Gencaro development program Fast Track designation and a Special Protocol Assessment (SPA) agreement. For more information, please visit <font style="text-decoration:underline;">www.arcabio.com</font> or follow the Company on <font style="text-decoration:underline;">LinkedIn</font>. </p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Safe Harbor Statement</p>
<p style="margin-bottom:16pt;text-align:justify;margin-top:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the ability of ARCA&#8217;s financial resources to support its operations through the end of the third quarter of 2020, potential future development plans for AB201 and Gencaro, the expected features and characteristics of AB201 or Gencaro, including the potential for AB201 to treat COVID-19/CAC, the potential for genetic variations to predict individual patient response to Gencaro, Gencaro&#8217;s potential to treat AF, future vaccines and/or treatment options for patients with COVID-19, future treatment options for patients with AF, and the potential for Gencaro to be the first genetically targeted AF prevention treatment<font style="font-size:11.5pt;">. </font>Such statements are based on management's current expectations and involve risks and uncertainties.&nbsp;&nbsp;Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA&#8217;s financial resources and whether they will be sufficient to meet its business objectives and operational requirements; ARCA may not be able to raise sufficient capital on acceptable terms, or at all, to continue development of AB201 or Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not be confirmed in future trials; the protection and market exclusivity provided by ARCA&#8217;s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes.&nbsp;&nbsp;These and other factors are identified and described in more detail in ARCA&#8217;s filings with the Securities and Exchange Commission, including without limitation ARCA&#8217;s annual report on Form 10-K for the year ended December&#160;31,&#160;2019, and subsequent filings. ARCA disclaims any intent or obligation to update these forward-looking statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investor &amp; Media Contact:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derek Cole</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">720.940.2163</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">derek.cole@arcabio.com</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gvebfb4t3mpa000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvebfb4t3mpa000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" "> =$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]\-6U:VT+
M39[R\GBM;2U0R332L%2-0,DDGH!7R?\ '#]O^]O[R;3_  3&+.T4E#J4\>Z:
M7WC1N%'NP).>BFJW[>_QUN-9\3'P7I\S1Z?IVV34-O'VB8X94/JJ @XZ;CR,
MJ*^< ,FOYI\2O$[%QQ<\IRB?)&#M.:^)R6ZB^B6S:U;O9VW_ $;AWANDZ2Q6
M*5V]4GLEW?>_W6-CQ-\0==\9W#2:MK&I:B[GG[1</(![ $X ]AQ62D+/5BWT
M]BY5E8,IP01TK5LM)SCY37X)6Q%6O-RJ-RD]VVV_O9]JN2G&T59&9_9#I(RM
MU4_G4T>CD_\ ZJ[A?")U'PQ#J$:#=:2"TN<9+<@F)SDXY 9,#  B'<\Q0^'^
M/N_I73++:J:?1JZ]/ZT?FFC#ZTF<M=>'O*MK60(R^=&6)QPQ#L/Z"J<FCXKU
MCQ'X*^R^"/#MUY;#[4EP,^NV7'K[US-QH&%^[^E;8S*:M&:B_P"6+_\  HI_
MJ9T<8I*Z[O\ !V.';2Y/+=P/ECQD_7_/Z&JY5HF[@CH:]#\7>$6\/6]G9R*R
MW30K=7 *@;#( R+D$Y'EE&YP09&&.*Y2]TO:>E<6)P]3#S]G-:K?R?;U6S\[
MG12KJ:NC4\#_ !W\7_#JY232?$&I0QH?]1)*98&^L;97\<9KZF_9T_;;L?B9
M>6^B^(HH=)UN9A'!*A(MKQCT49)*.>@!)!/0Y(%?&,]HT;'Y3QU]JA!VG(X/
MJ*^OX7X^S;):L94:CG3ZPDVXM>7\K\U\[K0\_,LCPN,@U.-I=)+?_@_,_5"B
MO&/V+?CM-\6_A[)8ZG,TVM:"5AFD=LO<Q$'RY#ZMP5/4Y4$_>KV>O[(R3.,/
MFF!IX_"OW)J_FGLT_-.Z?FC\EQF$J8:M*A4WB_Z?S"BBBO4.4**** "BBD9M
MM &+XK^)/A[P'>Z9;:YKNC:-<:U<BSTZ.^OHK=[^<](H@[ R.<CY5R>>E;8.
M17X,_P#!:_\ :IE^/_[;NJ:;I]Q(NB_#<MH-EM)7_28W)NI1S][S@4!'584-
M?L5^PI^T;'^U;^RCX+\;>9"U]J=@L6I)&>(;V(F*=<=5_>(S 'G:RGD$$Q&=
MW8N4;*YZY1115D!1110 45PO[2WPHU;XX_ [Q!X3T/Q9J7@?5-:A2&#7+!"U
MQ8$2(Y*A70_,JE#AU.&."*_-WXJ_\$LOVQ?!$>H7GA/X]:[XN@M1NMK=?&&I
M:=J%YST"2,85;O\ -.!QU]9E)KH5&*?4_5RBOYV_%O[:?[3'P"\;ZAX;\0?$
MCXG:/KVC3"*[LM4U6>66%@ RY$K-N5E(8'E75@02"#574_\ @J#^T%JZJLOQ
M:\8)MSCR+H0'GU* 9_'I6?M33V1_1=17XM_LZ?LC_MM_M8>$;7Q+#\3/&GAC
M0]4MENK"Z\0^--0M1?QDX4QPPF255(&X,\:*RD,I8$$^C'_@DQ^V>/F_X:!M
M]W3_ )'C7/\ Y'JN=]B>1+J?J]17X<_&?QC^VQ_P3DN3>>)/&7C7^Q[R5K:#
M5KC4%\0Z9,01C#7 E$);JJR+&[ -@'#8]1_9;_X.+?$6B:A:Z?\ %SPO9ZWI
MN%C;5]"3[->Q8!R\D#-Y4I9MO"&$*-V W H]HNH>S?0_76BN9^$7QC\,?'KP
M#I_BCP?K5CK^@ZI&)+>[M7RI]593AD=>C(X#*<A@""*Z:M#,**** "BD9L5\
M6?ML?\%O/AC^R[=WF@^&U/Q$\86Q,<EMI]P$TZR<%<K-=88%@&;Y8ED(9"KF
M,\TG)+<:3>Q]J51UOQ+I_AJV:;4;ZSL(44LTES.L2@#J26(&*_#+Q!_P4E_:
MI_X* >/5\*^#=1U>RFU HT>C^#8#8B!00ID>Y!,R1Y9=[23",9&<"O:?A/\
M\&\WC_XJ,=>^+/Q)M](U;4#'<36]K&^LWK[AEUGN)'15E4\93SE)R0Q'6/:-
M[(OV=MV?I)?_ +;'P;TJ;R[KXM?#.VDR1ME\46*-D=1@RUL>%_VE?AWXXNUM
M]%\>^"]8N&SB.RUNVN'..O".3W'YU\;Q?\&Y/P16,!O$_P 46;')_M*Q'/\
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M>6[V]Q"=KHXZ>GU!'((X(.15?1-+R!7M/PN;3O'NFV_AWQ!^[EC&S3+\?ZR
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M.@I=?M+>/M2X\RS\,K:J>^);J)C_ .B17['"JI;$U'J%%%%:&84444 %%%%
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MVEW&KI<0Z-"7#RZ9 ZI' 2%<Q[HE4,P4@,[''.*^\%_X. ?B B@+^SQJ"@<
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M $__ *4&OSH\*V,>J>)]-M9EW0W%U%%( <95G //T-?HO_P<G_\ )>/AO_V
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MM)59->G+!?FF?F_&4D\<DND5^;?ZA1103@5^P'R8C?=K\$/^"JWQ^U#]M_\
MX* W6B^'9/[2T_1[R+PCX>ABE#17,HFV/(ISM/FW#MAQU01\D 5^I?\ P5D_
M;EM?V,OV:-2&GZ@D7CKQ7#)IV@01R8F@9AMDN_4"%3N!Z%S&.YQ^87_!"KX3
MV7Q5_P""@^BWFH30;?".FW>OQPS*&^US)L@C S_$C7 E!ZCR<^]8U'=\IM35
MES'[5?LU_!/3_P!G#X"^$_ ^F*OV7PUIL5F77/[^4#,LI]Y)"[GW<].E=Q0!
MBBMC$*&&1110!^"/_!;/]G!?V?OVZM<N[.".'1O'<*^(K18T8)')*62Y4D\;
MC.DDA X"S)TKSO\ X)K_ +2B_LI_MG>"O%5U=1VNBR7@TS67D+>6EE<?NI9&
M"\D1Y$H !YB'!Z5^E?\ P<5_"2S\5?LH>&_%S974O".NK;QDGAH+M"LJX]=\
M4!SV"MZU^+U<TM)'3%WB?U3HXD7<IRIZ'UI:^//^".W[>^F_M8?LZZ;X<U;4
MD_X6#X+M$LM2MYI<SZA;Q@)%>+DY?<NU9&Y(DR3@.N?L.NB+NKG/)6=@HHH)
MP*8C\??^#D__ )+Q\-_^P!/_ .E!K\[O O\ R.^C_P#7]!_Z,6OO?_@XW\;6
M>M?M7>$-%MYHYKC1/#:O=!3DPO-<2L$;T.Q%;'HX/>O@#PWJ*Z1XBL+N0%H[
M6YCF8#N%8$_RKEEN=4=C^INBJ?A[7[/Q5H5GJFG74-[I^HP)=6MQ"VZ.>)U#
M(ZGNK*00?0U<KJ.4_/G_ (+L_L!?\+S^%'_"UO#-FTGB[P3;%=3AB^]J6F+N
M9CM .Z2 DN#D?NS+G<0@K\7:_JFFB6>-E9596&"",@BOP2_X+ ?L#M^QE^T)
M)J6AV;1^ /&CR7FD%%'EZ?-G,UG[!"0R<?<=1DE&-8U(]4;4Y=#[;_X(4?\
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MFZC<6%AK,VB7=^]W$CLB7,;Y6##@!Q\KJ P&6ZG]%.M&*]"2N8Q=C\'?B/\
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M'CG!KI=M &*N,;$2E?H0WMA!J5G-;W$,5Q;W"&.6*1 R2*1@JP/!!'!!ZU\
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MQU;P$*9M3\+7)NBN. );8HIQ_>96/)R2:_6;&:,4>SMLP]I?='Y]_P##SO\
M::_Z-*\4?]_;K_Y'HK]!,457*^XN9=@HHHJB VT=*** "BBB@ HHHH *,444
M &WFBBB@ HHHH ***#TH ,XK/M_%6F7>O3:5#J%E+J=O&)I;1)E::)"<;F3.
M0,D<D=Z^;?V_M>\4^!!9W5CXSOK73]9D,,>DVZ"W:)4C7>WFH0[J6/(;IO Z
M5O?\$]?A@WASX97?B2ZC;[=XDGS&SCYA!&2 <GGYG+GW 4UGS^]RFGL_=YCZ
M$HHHK0S#- .:1N17QY\'?%WQAN?VFK>WU1O$#0->$:E;W"/]AAM\G<R@_(H
M^XR]3CDYYF4K%1C<^Q**!THJB0HHHH ***,T %%)NI0<T %%%% !NJCIWBC3
M=7U:\L;74+.YO=/V_:H(IE>2WW9V[U!RN<'KZ5\O_M]:KXJ\"/9S0^-KY=/U
MR:1(]*@C%L8415S^\3!D7+ '=_>'7MV/_!//X>?\(Q\'9M;FC7[5XDN6E#Y.
MXP1DH@/_  +S3[AA6?/>7*:<EH\Q[[1116AF%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !03@45QOQ^^)B_"/X2:UKFY!<6\!CM5;D/._P L8QW&
MX@GV!H;MJ"U=CY+_ &HM<N_VB/VJX?#.FLS0V-PNC6YV$B-PW[^1AUPK;LD?
MPQ@U]??\)1X3^$&CZ;HMYK6BZ'#:VR16L%Y>QP,8T&T$!V!/3KZU\-_LL2:V
M?'=U)X9LUU#Q==0M;V$T_,.FA_\ 77<A/'RK\H!SDR'AB K=M^U)^R<GPK^&
M:>*+[Q)J&M>(;B]2*]DN2/+N"X;[F<MD8'5CD \#I7-&32<CJE%-J-S[0L-0
MM]5L8;JUFAN;:X0212Q.'CD4C(96'!!'((J:O&?V"9[R;]F[2_M6[RTN;A;4
MGO%YA_\ 9]X_"O4_&7B9?!WA>^U1K6\OOL4+2BWM(C+-,1T5%'4D\>@ZGBMX
MRNKG/*-G8GU[Q#I_A?3)+S5+ZSTVSC(#SW4RPQ(2<#+,0!DG%1^'/%.E^,;
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M9_ZZ#WJO:/FL+V:Y;W/KRBBLGQOXWTOX=^&;K6-8NX[.PLUW22/W]% ZEB>
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:0@,",CUJWLQ2T4 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
